Jianxing Tang

机构：Simcere Pharmaceutical (China), Fosun Pharma (China)

发表论文 13 篇 · 总被引 100 次 · h-index 6

代表论文

• Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial (2023 · The Lancet Regional Health - Western Pacific · 被引 33)
• Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment (2021 · BMC Cancer · 被引 22)
• SCR‐7952, a highly selective MAT2A inhibitor, demonstrates synergistic antitumor activities in combination with the S ‐adenosylmethionine‐competitive or the methylthioadenosine‐cooperative protein arginine methyltransferase 5 inhibitors in methylthioadenosine phosphorylase‐deleted tumors (2024 · MedComm · 被引 10)
• A Phase I First-in-Human, Open-Label Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0500, a Humanized GPRC5D-BCMA-CD3 Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma (2024 · Blood · 被引 7)
• RISK ASSESSMENT OF HEAVY METALS IN SOILS CONTAMINATED BY SMELTING WASTE FOR THE PERSPECTIVE OF CHEMICAL FRACTION AND SPATIAL DISTRIBUTION (2021 · Journal of Environmental Engineering and Landscape Management · 被引 7)
• Abstract 2089: Evaluation of fruquintinib, a potent and selective oral VEGFR inhibitor, in combination with targeted therapies or immune checkpoint inhibitors in preclinical tumor models (2017 · Cancer Research · 被引 7)